Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells
Curcumin (Cur), a promising anticancer drug, kills tumor cells through either diminishing or promoting reactive oxygen species (ROS) generation. In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug, could improve t...
Gespeichert in:
| Veröffentlicht in: | Pharmazie 2006-08, Vol.61 (8), p.710-716 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 716 |
|---|---|
| container_issue | 8 |
| container_start_page | 710 |
| container_title | Pharmazie |
| container_volume | 61 |
| creator | Chen, Jie Bai, Hai Wang, Cunbang Kang, Jiuhong |
| description | Curcumin (Cur), a promising anticancer drug, kills tumor cells through either diminishing or promoting reactive oxygen species (ROS) generation. In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug,
could improve the anticancer activity of low concentrations of Cur in human leukemia cells (HL-60). HL-60 cells were treated with Cur, TSA or their combinations; cell proliferation arrest, lactate dehydrogenase (LDH) release and cell viability were measured as indicators of cell damage. Reactive
oxygen species (ROS) accumulation and the acetylation of histones were also measured. The cytotoxicity of Cur and TSA increased in a time and dose-dependent manner. Low Cur (no more than 20 μM) diminished the ROS generation in HL-60 cells, while high Cur (50 and 100 μM) promoted that.
In contrast, TSA showed no influence on ROS generation. When their effects on histone acetylation were determined, low Cur showed no effect, while TSA significantly increased that. As expected, combinations of low Cur and TSA could not only diminish ROS generation, but also increase histone
acetylation, and hence showed a more significant cytotoxicity in HL-60 cells. Since the extra ROS generation may also harm normal cells, instead of using high Cur, combining low Cur with TSA is obviously a better strategy to improve the anticancer activity of Cur. |
| format | Article |
| fullrecord | <record><control><sourceid>pubtec_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16964716</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ingid>govi/pharmaz/2006/00000061/00000008/art00014</ingid><sourcerecordid>govi/pharmaz/2006/00000061/00000008/art00014</sourcerecordid><originalsourceid>FETCH-LOGICAL-i270t-f25a0fd40afac85787c23f6663677cda05a7de656cd15aadaa8fadf818dd70553</originalsourceid><addsrcrecordid>eNo1T8tOwzAQzAFES-EXkH8gkp2HHY5VeUqVuJSztfjRuMR2ZDtB5esxtKxWmtVodjRzUSwxrknJSNMsiusYDxhXtKLdVbEg9J42jNBlYXbBiN7HBMk4tEbGjsHPKqLUKwQuGQFOqIBAJDObdEReo8F_IeEz7VLIb97FX1ZMQUw2m-TtJwsODWr6VNYAEmoY4k1xqWGI6vaMq-L96XG3eSm3b8-vm_W2NBXDqdRVC1jLBoMG0bWsY6KqNaW0powJCbgFJhVtqZCkBZAAnQapO9JJyXDb1qvi7uQ7Th9WST4GYyEc-X_nLHg4CYzb5wrAD34KLkfiez8bPvYQLHzzCmPK8d9Qcj5wxyGkjKSpfwBceWrX</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>IngentaConnect Free/Open Access Journals</source><creator>Chen, Jie ; Bai, Hai ; Wang, Cunbang ; Kang, Jiuhong</creator><creatorcontrib>Chen, Jie ; Bai, Hai ; Wang, Cunbang ; Kang, Jiuhong</creatorcontrib><description>Curcumin (Cur), a promising anticancer drug, kills tumor cells through either diminishing or promoting reactive oxygen species (ROS) generation. In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug,
could improve the anticancer activity of low concentrations of Cur in human leukemia cells (HL-60). HL-60 cells were treated with Cur, TSA or their combinations; cell proliferation arrest, lactate dehydrogenase (LDH) release and cell viability were measured as indicators of cell damage. Reactive
oxygen species (ROS) accumulation and the acetylation of histones were also measured. The cytotoxicity of Cur and TSA increased in a time and dose-dependent manner. Low Cur (no more than 20 μM) diminished the ROS generation in HL-60 cells, while high Cur (50 and 100 μM) promoted that.
In contrast, TSA showed no influence on ROS generation. When their effects on histone acetylation were determined, low Cur showed no effect, while TSA significantly increased that. As expected, combinations of low Cur and TSA could not only diminish ROS generation, but also increase histone
acetylation, and hence showed a more significant cytotoxicity in HL-60 cells. Since the extra ROS generation may also harm normal cells, instead of using high Cur, combining low Cur with TSA is obviously a better strategy to improve the anticancer activity of Cur.</description><identifier>ISSN: 0031-7144</identifier><identifier>PMID: 16964716</identifier><language>eng</language><publisher>Germany: Govi-Verlag</publisher><subject>Acetylation ; Acetylcysteine - pharmacology ; Antineoplastic Agents, Phytogenic - pharmacology ; Antioxidants - pharmacology ; Ascorbic Acid - pharmacology ; Cell Line, Tumor ; Cell Proliferation ; Cell Survival - drug effects ; Curcumin - pharmacology ; Drug Synergism ; Histones - isolation & purification ; Histones - metabolism ; HL-60 Cells ; Humans ; Hydroxamic Acids - pharmacology ; Indicators and Reagents ; L-Lactate Dehydrogenase - metabolism ; Leukemia, Promyelocytic, Acute - drug therapy ; Protein Synthesis Inhibitors - pharmacology ; Reactive Oxygen Species - metabolism</subject><ispartof>Pharmazie, 2006-08, Vol.61 (8), p.710-716</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>288,314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16964716$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Bai, Hai</creatorcontrib><creatorcontrib>Wang, Cunbang</creatorcontrib><creatorcontrib>Kang, Jiuhong</creatorcontrib><title>Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells</title><title>Pharmazie</title><addtitle>Pharmazie</addtitle><description>Curcumin (Cur), a promising anticancer drug, kills tumor cells through either diminishing or promoting reactive oxygen species (ROS) generation. In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug,
could improve the anticancer activity of low concentrations of Cur in human leukemia cells (HL-60). HL-60 cells were treated with Cur, TSA or their combinations; cell proliferation arrest, lactate dehydrogenase (LDH) release and cell viability were measured as indicators of cell damage. Reactive
oxygen species (ROS) accumulation and the acetylation of histones were also measured. The cytotoxicity of Cur and TSA increased in a time and dose-dependent manner. Low Cur (no more than 20 μM) diminished the ROS generation in HL-60 cells, while high Cur (50 and 100 μM) promoted that.
In contrast, TSA showed no influence on ROS generation. When their effects on histone acetylation were determined, low Cur showed no effect, while TSA significantly increased that. As expected, combinations of low Cur and TSA could not only diminish ROS generation, but also increase histone
acetylation, and hence showed a more significant cytotoxicity in HL-60 cells. Since the extra ROS generation may also harm normal cells, instead of using high Cur, combining low Cur with TSA is obviously a better strategy to improve the anticancer activity of Cur.</description><subject>Acetylation</subject><subject>Acetylcysteine - pharmacology</subject><subject>Antineoplastic Agents, Phytogenic - pharmacology</subject><subject>Antioxidants - pharmacology</subject><subject>Ascorbic Acid - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Cell Survival - drug effects</subject><subject>Curcumin - pharmacology</subject><subject>Drug Synergism</subject><subject>Histones - isolation & purification</subject><subject>Histones - metabolism</subject><subject>HL-60 Cells</subject><subject>Humans</subject><subject>Hydroxamic Acids - pharmacology</subject><subject>Indicators and Reagents</subject><subject>L-Lactate Dehydrogenase - metabolism</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Reactive Oxygen Species - metabolism</subject><issn>0031-7144</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1T8tOwzAQzAFES-EXkH8gkp2HHY5VeUqVuJSztfjRuMR2ZDtB5esxtKxWmtVodjRzUSwxrknJSNMsiusYDxhXtKLdVbEg9J42jNBlYXbBiN7HBMk4tEbGjsHPKqLUKwQuGQFOqIBAJDObdEReo8F_IeEz7VLIb97FX1ZMQUw2m-TtJwsODWr6VNYAEmoY4k1xqWGI6vaMq-L96XG3eSm3b8-vm_W2NBXDqdRVC1jLBoMG0bWsY6KqNaW0powJCbgFJhVtqZCkBZAAnQapO9JJyXDb1qvi7uQ7Th9WST4GYyEc-X_nLHg4CYzb5wrAD34KLkfiez8bPvYQLHzzCmPK8d9Qcj5wxyGkjKSpfwBceWrX</recordid><startdate>20060801</startdate><enddate>20060801</enddate><creator>Chen, Jie</creator><creator>Bai, Hai</creator><creator>Wang, Cunbang</creator><creator>Kang, Jiuhong</creator><general>Govi-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20060801</creationdate><title>Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells</title><author>Chen, Jie ; Bai, Hai ; Wang, Cunbang ; Kang, Jiuhong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i270t-f25a0fd40afac85787c23f6663677cda05a7de656cd15aadaa8fadf818dd70553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acetylation</topic><topic>Acetylcysteine - pharmacology</topic><topic>Antineoplastic Agents, Phytogenic - pharmacology</topic><topic>Antioxidants - pharmacology</topic><topic>Ascorbic Acid - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Cell Survival - drug effects</topic><topic>Curcumin - pharmacology</topic><topic>Drug Synergism</topic><topic>Histones - isolation & purification</topic><topic>Histones - metabolism</topic><topic>HL-60 Cells</topic><topic>Humans</topic><topic>Hydroxamic Acids - pharmacology</topic><topic>Indicators and Reagents</topic><topic>L-Lactate Dehydrogenase - metabolism</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Reactive Oxygen Species - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Bai, Hai</creatorcontrib><creatorcontrib>Wang, Cunbang</creatorcontrib><creatorcontrib>Kang, Jiuhong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Pharmazie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Jie</au><au>Bai, Hai</au><au>Wang, Cunbang</au><au>Kang, Jiuhong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells</atitle><jtitle>Pharmazie</jtitle><addtitle>Pharmazie</addtitle><date>2006-08-01</date><risdate>2006</risdate><volume>61</volume><issue>8</issue><spage>710</spage><epage>716</epage><pages>710-716</pages><issn>0031-7144</issn><abstract>Curcumin (Cur), a promising anticancer drug, kills tumor cells through either diminishing or promoting reactive oxygen species (ROS) generation. In this study, it was investigated whether trichostatin A (TSA), a specific histone deacetylase (HDAC) inhibitor and a new anticancer drug,
could improve the anticancer activity of low concentrations of Cur in human leukemia cells (HL-60). HL-60 cells were treated with Cur, TSA or their combinations; cell proliferation arrest, lactate dehydrogenase (LDH) release and cell viability were measured as indicators of cell damage. Reactive
oxygen species (ROS) accumulation and the acetylation of histones were also measured. The cytotoxicity of Cur and TSA increased in a time and dose-dependent manner. Low Cur (no more than 20 μM) diminished the ROS generation in HL-60 cells, while high Cur (50 and 100 μM) promoted that.
In contrast, TSA showed no influence on ROS generation. When their effects on histone acetylation were determined, low Cur showed no effect, while TSA significantly increased that. As expected, combinations of low Cur and TSA could not only diminish ROS generation, but also increase histone
acetylation, and hence showed a more significant cytotoxicity in HL-60 cells. Since the extra ROS generation may also harm normal cells, instead of using high Cur, combining low Cur with TSA is obviously a better strategy to improve the anticancer activity of Cur.</abstract><cop>Germany</cop><pub>Govi-Verlag</pub><pmid>16964716</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-7144 |
| ispartof | Pharmazie, 2006-08, Vol.61 (8), p.710-716 |
| issn | 0031-7144 |
| language | eng |
| recordid | cdi_pubmed_primary_16964716 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; IngentaConnect Free/Open Access Journals |
| subjects | Acetylation Acetylcysteine - pharmacology Antineoplastic Agents, Phytogenic - pharmacology Antioxidants - pharmacology Ascorbic Acid - pharmacology Cell Line, Tumor Cell Proliferation Cell Survival - drug effects Curcumin - pharmacology Drug Synergism Histones - isolation & purification Histones - metabolism HL-60 Cells Humans Hydroxamic Acids - pharmacology Indicators and Reagents L-Lactate Dehydrogenase - metabolism Leukemia, Promyelocytic, Acute - drug therapy Protein Synthesis Inhibitors - pharmacology Reactive Oxygen Species - metabolism |
| title | Trichostatin A improves the anticancer activity of low concentrations of curcumin in human leukemia cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T12%3A31%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubtec_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Trichostatin%20A%20improves%20the%20anticancer%20activity%20of%20low%20concentrations%20of%20curcumin%20in%20human%20leukemia%20cells&rft.jtitle=Pharmazie&rft.au=Chen,%20Jie&rft.date=2006-08-01&rft.volume=61&rft.issue=8&rft.spage=710&rft.epage=716&rft.pages=710-716&rft.issn=0031-7144&rft_id=info:doi/&rft_dat=%3Cpubtec_pubme%3Egovi/pharmaz/2006/00000061/00000008/art00014%3C/pubtec_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16964716&rft_ingid=govi/pharmaz/2006/00000061/00000008/art00014&rfr_iscdi=true |